Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report report published on Sunday morning. The brokerage issued a hold rating on the medical research company’s stock.

Separately, BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a research report on Wednesday, December 11th.

Accelerate Diagnostics Stock Up 4.1 %

Shares of AXDX stock opened at $1.15 on Friday. The firm has a fifty day moving average of $1.18 and a 200-day moving average of $1.49. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $2.09. The company has a market capitalization of $28.68 million, a price-to-earnings ratio of -0.40 and a beta of 0.55.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its position in Accelerate Diagnostics by 6.9% in the fourth quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock valued at $163,000 after purchasing an additional 8,777 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Accelerate Diagnostics in the third quarter valued at $34,000. Jane Street Group LLC bought a new position in Accelerate Diagnostics in the fourth quarter valued at $27,000. Finally, Renaissance Technologies LLC grew its position in Accelerate Diagnostics by 160.6% in the fourth quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 65,984 shares in the last quarter. Institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.